Solvotrin Therapeutics

solvotrin therapeutics is a drug development company focused on chemical modifications of known drugs. solvotrin’s intellectual property offers a major opportunity with novel, patent-protected new chemical entities at the cutting edge of therapeutics. it arises from the discovery in trinity college dublin of the first “true” aspirin prodrugs. solvotrin’s patented linker releases aspirin and various associated molecules post absorption with the required speed and recovery to improve effectiveness, while avoiding the direct gut toxicity associated with aspirin. the company is focussed on developing its lead compound st0702 for colorectal cancer. exceptionally the development plan is designed to enable the option of pursuing other markets, including other cancer opportunities and a rare cholesterol disease, where st0702 and other compounds in the platform have demonstrated highly impressive results.